Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL

Trial Profile

Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Colon cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms NICHE
  • Most Recent Events

    • 07 Mar 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jun 2019.
    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress, recruitment for this study is ongoing and currently two patients have been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top